Effect of low doses of long-chain n−3 PUFAs on endothelial function and arterial stiffness: a randomized controlled trial

Sanders, Tom; Hall, Wendy L.; Maniou, Zoitsa; Lewis, Fiona; Seed, Paul; Chowienczyk, Phil

doi:10.3945/ajcn.111.018036

Cited by 90 publications

(97 citation statements)

References 40 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Data are presented for the 310 participants out of 367 randomised to treatment, who completed the study and for whom DNA was available for genetic analysis. The number of participants allocated and drop-out rates did not differ significantly between treatment groups (Sanders et al 2011). Women, mostly postmenopausal, outnumbered men by approximately 1.6:1 and about 20 % of the sample was non-white, with similar proportions of Asian and black participants.…”

Section: Resultsmentioning

confidence: 83%

“…Women, mostly postmenopausal, outnumbered men by approximately 1.6:1 and about 20 % of the sample was non-white, with similar proportions of Asian and black participants. The average BMI (25.64 ± 3.80 kg/m 2 ) and the mean waist circumferences (95.31 ± 9.60 cm in men and 84.37 ± 10.67 cm in women) were slightly greater than cut-offs, indicating risk of metabolic syndrome (BMI [ 25 kg/m 2 and waist circumference[94 cm in men and[80 cm in women) (Sanders et al 2011). There were no significant differences in these measures between the four treatment groups at baseline (P [ 0.05).…”

Section: Resultsmentioning

confidence: 92%

“…The MARINA trial was a single-centre dietary intervention study of randomised double-blind parallel design, to test the effects of three daily doses of EPA and DHA on endothelial function and CVD risk factors (Sanders et al 2011). The study was conducted at King's College London between April 2008 and October 2010 and approved by the St Thomas' Hospital NHS Research Ethics Committee (NREC 08/H0802/3).…”

Section: Subjectsmentioning

confidence: 99%

“…The study was registered at controlled-trials.com as ISRCTN66664610. Written informed consent was given by participants, who were healthy non-smoking men and women aged between 45 and 70 years, recruited through media advertisements and screened as described previously (Sanders et al 2011). The participants (a total of 367) were randomised to treatment.…”

Section: Subjectsmentioning

confidence: 99%

“…Plasma total fatty acids were determined by capillary GLC as previously described (Sanders et al 2011), substituting toluene for benzene and using pentadecanoic acid as an internal standard (Lepage and Roy 1988).…”

Section: Blood Sampling and Analysismentioning

confidence: 99%

See 4 more Smart Citations

ELOVL2 gene polymorphisms are associated with increases in plasma eicosapentaenoic and docosahexaenoic acid proportions after fish oil supplement

et al. 2013

Self Cite

View full text Add to dashboard Cite

Fish oil supplementation provides an inconsistent degree of protection from cardiovascular disease (CVD), which may be attributed to genetic variation. Single nucleotide polymorphisms (SNPs) in the elongation-ofvery-long-chain-fatty-acids-2 (ELOVL2) gene have been strongly associated with plasma proportions of n-3 longchain polyunsaturated fatty acids (LC-PUFA). We investigated the effect of genotype interaction with fish oil dosage on plasma n-3 LC-PUFA proportions in a parallel doubleblind controlled trial, involving 367 subjects randomised to treatment with 0.45, 0.9 and 1.8 g/day eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (1.51:1) or olive oil placebo for 6 months. We genotyped 310 subjects for ELOVL2 gene SNPs rs3734398, rs2236212 and rs953413. At baseline, carriers of all minor alleles had lower proportions of plasma DHA than non-carriers (P = 0.021-0.030). Interaction between genotype and treatment was a significant determinant of plasma EPA (P \ 0.0001) and DHA (P = 0.004-0.032). After the 1.8 g/day dose, carriers of ELOVL2 SNP minor alleles had approximately 30 % higher proportions of EPA (P = 0.002-0.004) and 9 % higher DHA (P = 0.013-0.017) than non-carriers. Minor allele carriers could therefore particularly benefit from a high intake of EPA and DHA in maintaining high levels of plasma n-3 PUFA conducive to protection from CVD.

show abstract

Section: Resultsmentioning

confidence: 83%

Section: Resultsmentioning

confidence: 92%

Section: Subjectsmentioning

confidence: 99%

Section: Subjectsmentioning

confidence: 99%

Section: Blood Sampling and Analysismentioning

confidence: 99%

See 3 more Smart Citations